The American Journal of Medicine
Volume 122, Issue 9 , Pages 874.e9-874.e15 , September 2009

High-dose N-acetylcysteine for the Prevention of Contrast-induced Nephropathy

  • Hariprasad Trivedi, MD

      Affiliations

    • Division of Nephrology and Kidney Disease Center, Medical College of Wisconsin, Milwaukee
    • Corresponding Author InformationRequests for reprints should be addressed to Hariprasad Trivedi, MD, 9200 W. Wisconsin Ave, Milwaukee, WI 53226
    • ,
  • Sumanth Daram, MD

      Affiliations

    • Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee
    • ,
  • Aniko Szabo, PhD

      Affiliations

    • Department of Biostatistics, Medical College of Wisconsin, Milwaukee
    • ,
  • Antonio L. Bartorelli, MD

      Affiliations

    • Centro Cardiologico Monzino, Institute of Cardiology, University of Milan, Milan, Italy
    • ,
  • Giancarlo Marenzi, MD

      Affiliations

    • Centro Cardiologico Monzino, Institute of Cardiology, University of Milan, Milan, Italy

References 

  1. Yoshimasa Y, Fogo A, Beckman JD. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int. 1992;41:1008–1015
  2. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol Renal Physiol. 1990;258:F115–F120
  3. Parvez Z, Rahman MA, Moncada R. Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol. 1989;24:697–702
  4. Hanss BG, Valencia SH, Shah SV, Vari SC. The iron chelator desferoxamine prevents contrast media induced acute renal failure in the rabbit. J Am Soc Nephrol. 1990;1:612
  5. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal functions by acetylcysteine. N Engl J Med. 2000;343:180–184
  6. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–294
  7. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? (A meta-analysis). Am J Med. 2004;117:938–947
  8. Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:E23
  9. Miner SE, Dzavik V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690–695
  10. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography (A randomized controlled trial and review of the current literature). Eur Heart J. 2004;25:212–218
  11. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
  12. Briguori C, Colombo A, Violante A, et al. Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206–211
  13. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207
  14. Solomon R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int. 2006;(suppl):S46–S50
  15. Pannu N, Wiebe N, Tonelli M Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765–2779
  16. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–680
  17. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114–2118
  18. Kefer JM, Hanet CE, Boitte S, et al. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?. Acta Cardiol. 2003;58:555–560
  19. Efrati S, Dishy V, Averbukh M, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003;64:2182–2187
  20. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17:159–165
  21. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40:1136–1141
  22. Balderramo DC, Verdu MB, Ramacciotti CF, et al. Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography. Rev Fac Cien Med Univ Nac Cordoba. 2004;61:13–19
  23. Khalili H, Dashti-Khavidaki S, Tabifar H, et al. N-acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies. Therapy. 2006;6:773–777
  24. Poletti PA, Saudan P, Platon A, et al. I.V. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007;189:687–692
  25. Shaikh F, Maddikunta R, Museitif R, et al. A prospective randomized trial comparing normal saline and sodium bicarbonate with or without N-Acetylcysteine for prevention of contrast-induced nephropathy. Am J Cardiol. 2007;100(suppl 1):S122–S123[Abstract]
  26. Heng AE, Souweine B, Decalf V, et al. Is N-acetylcysteine an old-fashioned treatment to prevent contrast induced nephropathy when using bicarbonate hydration?. J Am Soc Nephrol. 2007;18:564A;[Abstract]
  27. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement (Quality of Reporting of Meta-analyses). Lancet. 1999;354:1896–1900
  28. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235–1241
  29. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  31. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998;352:609–613
  32. Campbell V, Chapman M, Faull R, et al. Does N-acetylcysteine prevent contrast nephrotoxicity in at risk critically ill patients? (A pilot study). Intern Med J. 2005;35(Suppl):A64;[Abstract]
  33. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–386
  34. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998;53:230–242
  35. Fenves AZ, Allgren RL. Radiocontrast dye-induced acute tubular necrosis (ATN): atrial natriuretic peptide vs. placebo. J Am Soc Nephrol. 1995;6:463;[Abstract]
  36. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality (A cohort analysis). JAMA. 1996;275:1489–1494
  37. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–375
  38. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existing chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548
  39. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic implications of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–2264
  40. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infraction. Circulation. 2003;108:2769–2775
  41. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of stay after coronary angiography. J Am Soc Nephrol. 2006;17:2871–2877
  42. Hoffmann U, Fischereder M, Krüger B, et al. The value of N-acetyl- cysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–410
  43. Zhu J, Yin R, Shao H, et al. N-acetylcysteine to ameliorate acute kidney injury in a rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg. 2007;133:696–703
  44. Ristikankare A, Kuitunen T, Kuitunen A, et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth. 2006;97:611–616
  45. Haase M, Haase-Fielitz A, Ratnaike S, et al. N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant. 2008;23:1581–1587

 Funding: None.

 Conflict of Interest: None.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00344-1

doi: 10.1016/j.amjmed.2009.01.035

The American Journal of Medicine
Volume 122, Issue 9 , Pages 874.e9-874.e15 , September 2009

Article Tools

* Image Usage & Resolution